AbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual MeetingApril 27, 2018 8:00 AM Abbvie (ABBV) PT Raised to $101 at Deutsche BankApril 27, 2018 7:49 AM Another AbbVie (ABBV) Beat Wears The Bears Down - Goldman SachsApril 27, 2018 6:40 AM Abbvie (ABBV) PT Lowered to $113 at Leerink PartnersApril 27, 2018 3:21 AM AbbVie (ABBV) Plans $7.5B Tender OfferApril 26, 2018 7:52 AM AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS GuidanceApril 26, 2018 7:48 AM AbbVie (ABBV) Submits BLA to FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque PsoriasisApril 25, 2018 8:45 AM AbbVie (ABBV) Says Upadacitinib Met Primary and Key Efficacy Endpoints in Phase 2b/3 RA Study in Japanese PatientsApril 25, 2018 8:36 AM